Autres langues Xilio Therapeutics, Inc.

Actions

XLO

US98422T2096

Recherche biotechnologique et médicale

Temps Différé Nasdaq 18:27:38 30/09/2026			Varia. 5j.	Varia. 1 janv.
9,080 ^USD	+1,59%		+1,57%	+1,31%

28/09	Xilio Therapeutics, Inc. annonce la nomination de Yariv J. Houvras, M.D., Ph.D., au poste de directeur médical	CI
12/08	Xilio Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

28/09	Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
28/09	Xilio Therapeutics, Inc. Announces Appointment of Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
02/09	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/08	Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
06/07	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06	Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index
29/06	Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer
29/06	Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
29/06	Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Index
29/06	Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell 3000E Value Benchmark
29/06	Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell 3000E Index
12/05	Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
12/05	Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
11/05	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7, 2026
08/05	Xilio Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/05	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/04	Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
17/04	Xilio Therapeutics Announces New Preclinical Data For XTX601, A Masked T Cell Engager Targeting CLDN18.2
16/04	Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
16/04	Xilio Therapeutics, Inc. Announces Board and Committee Changes
16/04	Xilio Therapeutics, Inc. Announces Board Changes
13/04	Certain Series C common stock warrants of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026.
13/04	Certain Warrants of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026.
13/04	Certain Pre-Funded Warrants of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026.